UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
You may also be interested in...
Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
UCB May Be Stagnating Today, But Promises There Will Be Growth Tomorrow
Generics hit UCB's 2009 sales hard, but the mid-cap pharma is looking to new drugs Cimzia and Vimpat for a return to growth.